Last reviewed · How we verify
Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aromatase inhibitor | aromatase-inhibitor | Pfizer | Aromatase inhibitor | Aromatase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease:
- Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease treatment updates — RSS
- Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease treatment updates — Atom
- Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-breast-cancer-in-postmenopausal-women-with-hormone-receptor-positive-or-hormone-receptor-negative-advanced-disease. Accessed 2026-06-10.
Related
- Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing